Nivolumab †Rx
Rx ICI: PD-1 ↓ → T-cell ↑; OS/PFS across melanoma/NSCLC/RCC/HNSCC/MSI-high; irAE management key.
Forms: IV infusion (10 mg/mL concentrate) · Prefilled syringes (100 mg/10 mL, 240 mg/24 mL)
Key Takeaway
Anti–PD-1 checkpoint inhibitor that restores exhausted T cells and delivers survival gains across multiple cancers (melanoma, NSCLC, RCC, HNSCC, others); requires vigilant monitoring for immune-related toxicities.
Evidence at a glance
20+ phase III approvals; OS HR 0.6-0.8 in frontline; durable 5y OS 30-50% in melanoma/NSCLC; meta-combination benefits with CTLA-4i/chemo; ongoing in adjuvant/metastatic.
How it may work
By binding PD-1 on T cells, nivolumab prevents engagement with PD-L1/PD-L2, reversing T-cell exhaustion and boosting cytotoxic activity and memory responses. Tumor control stems from renewed CD8⁺ infiltration and effector function. Durable response ‘tails’ on survival curves occur in subsets with immunogenic tumors or high neoantigen burden.
Targets & pathways
Curated mechanistic targets reported for this agent — how it may act on cells, not proof of a clinical effect.
Often studied / combined with
Combinations reported in the literature, not a protocol or a recommendation.
- Ipilimumab: CheckMate 067: 5y OS 52% in melanoma combo.
- Chemotherapy: CheckMate 9LA: OS HR 0.72 in NSCLC frontline.
- Curcumin: Preclinical irAE mitigation and T-cell boost.
- Resveratrol: Enhanced effector function in lung models.
Overlapping mechanisms
- PD-1: Cross-resistance with pembro/cemi; switch to CTLA-4 or LAG-3.
- T-Cell Activation: Redundant in hot tumors; consider tumor microenvironment priming.
Safety & interactions
Severity and how well-established each signal is are shown separately. Verify everything with your oncologist or pharmacist — absence here does not mean safe.
- corticosteroidsUse For IrAELowTheoreticalHigh-dose for toxicity; low-dose physiologic OK.
- immunosuppressantsAvoidHighTheoreticalBlunts efficacy (e.g., chronic steroids).
- IpilimumabSynergizeModerateTheoreticalHigher irAE but OS gains in melanoma.
Timing
- Outpatient: 30-min IV; monitor 1h post for reactions.
- q2-4w: Cycle-dependent; continuous until progression/tox.
References
- NBK567801: Nivolumab mechanism and approvals
- PMC11899125: T-cell reinvigoration biomarkers
- DOI 10.1186/s12943-024-02212-7: PD-1 blockade review
- DOI 10.1016/j.intimp.2024.113547: irAE management
- NEJM 2015: CheckMate 066 NSCLC trial
- PMC10221542: Natural compound synergies with ICIs
Research
No published studies for Nivolumab †Rx yet
New studies appear here once they’ve been reviewed. Browse all studies.
Dose: as studied, not a recommendation
Ranges seen in adjunct / practice use: 240–480 mg IV q2-4w (IV) Flat dose: 240 mg q2w or 480 mg q4w; weight-based alternatives, Most tumors 240 mg q2w; melanoma/RCC 480 mg q4w; infuse over 30 min; premed not required..
Clinical trials studying Nivolumab †Rx
4 ongoing · 0 completed · tracked from ClinicalTrials.gov. Recruiting is not the same as proven, and completed is not the same as positive — read the results. Not a recommendation.